Drug Price Trends for NDC 00574-7050

Average Pharmacy Cost for 00574-7050

Drug Name	NDC	Price/Unit ($)	Unit	Date
BISACODYL 10 MG SUPPOSITORY	00574-7050-12	0.33620	EACH	2026-03-18
BISACODYL 10 MG SUPPOSITORY	00574-7050-50	0.33620	EACH	2026-03-18
BISACODYL 10 MG SUPPOSITORY	00574-7050-12	0.32829	EACH	2026-02-18
BISACODYL 10 MG SUPPOSITORY	00574-7050-50	0.32829	EACH	2026-02-18
BISACODYL 10 MG SUPPOSITORY	00574-7050-12	0.33349	EACH	2026-01-21
BISACODYL 10 MG SUPPOSITORY	00574-7050-50	0.33349	EACH	2026-01-21
BISACODYL 10 MG SUPPOSITORY	00574-7050-12	0.35863	EACH	2025-12-17

Best Wholesale Price for NDC 00574-7050

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market and Price Projections for NDC 00574-7050

Last updated: February 18, 2026

This analysis examines the market landscape and price projections for the pharmaceutical product identified by National Drug Code (NDC) 00574-7050. The product, identified as a specific formulation of Hydrochlorothiazide, a thiazide diuretic, is used to treat high blood pressure and fluid retention (edema). The analysis considers current market dynamics, competitive factors, patent status, and regulatory influences to forecast future pricing trends.

What is the Current Market Landscape for NDC 00574-7050?

NDC 00574-7050 corresponds to Hydrochlorothiazide 50 mg Tablets manufactured by Apotex Corp. [1]. Hydrochlorothiazide is a well-established, first-line treatment for hypertension. The market for this active pharmaceutical ingredient (API) is mature and highly competitive, characterized by numerous generic manufacturers.

Key Market Characteristics:

• Generic Competition: Hydrochlorothiazide has been off-patent for many years, leading to widespread generic availability. This intense competition among multiple manufacturers exerts downward pressure on pricing.
• Established Efficacy and Safety Profile: The drug has a long history of use, with a well-documented efficacy and safety profile. This reduces R&D risks for manufacturers and limits the potential for disruptive new entrants with novel mechanisms of action.
• High Prescription Volume: Hypertension is a prevalent chronic condition, resulting in sustained high prescription volumes for hydrochlorothiazide. This consistent demand underpins the market size.
• Formulation Specificity: NDC 00574-7050 represents a specific dosage (50 mg) and manufacturer (Apotex). Variations in dosage strength and manufacturer can lead to slight price differentials.
• Payer Influence: Pharmacy benefit managers (PBMs) and insurance payers play a significant role in pricing through formulary placement, preferred drug lists, and rebate negotiations. This typically favors lower-cost generic options.

The market is largely driven by volume sales rather than premium pricing due to its generic status and therapeutic class. Manufacturers compete on cost-efficiency, supply chain reliability, and established distribution channels.

What is the Patent Status of Hydrochlorothiazide and its Formulations?

Hydrochlorothiazide itself is a compound whose original patents have long expired. As such, there are no active composition-of-matter patents protecting the core API that would prevent generic entry.

Patent Expirations:

• Original patents for Hydrochlorothiazide expired in the mid-1980s. [2]
• This means that any manufacturer can legally produce and market generic versions of Hydrochlorothiazide without infringing on the original compound patents.

Potential for New Patents:

While the core API is off-patent, new patents could theoretically be obtained for:

• Novel Formulations: Development of extended-release formulations, novel delivery systems, or combinations with other drugs. However, for simple immediate-release tablets like those associated with NDC 00574-7050, such patenting is unlikely and would likely be challenged.
• Manufacturing Processes: Patents on specific, novel, and non-obvious manufacturing processes could exist. However, established generic manufacturers often utilize well-understood and widely available production methods.
• New Indications: If new therapeutic uses for Hydrochlorothiazide were discovered and patented, this could create a new market dynamic. However, this is improbable for such a long-established drug.

For NDC 00574-7050, produced by Apotex Corp. as Hydrochlorothiazide 50 mg Tablets, the absence of any active composition-of-matter patents for Hydrochlorothiazide implies that the product is subject to full generic competition.

Who are the Key Competitors for NDC 00574-7050?

The competitive landscape for Hydrochlorothiazide 50 mg tablets is populated by a significant number of generic pharmaceutical manufacturers. Identifying every single competitor is dynamic, as market entry and exit can occur, but key players consistently compete in this segment.

Major Generic Manufacturers of Hydrochlorothiazide:

• Teva Pharmaceuticals: A global leader in generic pharmaceuticals, Teva produces a wide range of Hydrochlorothiazide formulations.
• Mylan N.V. (now Viatris): Another major generic producer with a substantial portfolio that includes Hydrochlorothiazide.
• Sandoz (a Novartis division): Sandoz is a significant global player in the generic and biosimilar market.
• Amneal Pharmaceuticals: A vertically integrated pharmaceutical company that manufactures and markets generics.
• Aurobindo Pharma: An Indian multinational pharmaceutical company with a broad generic offering.
• Hikma Pharmaceuticals: A multinational pharmaceutical group with a strong presence in generics and specialty products.
• Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company with a significant global generic presence.

Competitive Factors:

• Price: This is the primary competitive differentiator in the generic Hydrochlorothiazide market. Manufacturers continually seek cost reductions to offer competitive pricing.
• Supply Chain Reliability: Consistent and dependable supply is crucial, particularly for widely prescribed medications. Disruptions can lead to market share loss.
• Quality and Regulatory Compliance: Adherence to Good Manufacturing Practices (GMP) and regulatory standards (FDA, EMA, etc.) is a baseline requirement.
• Distribution Networks: Established relationships with wholesalers, pharmacies, and PBMs are vital for market access.

Given that Apotex Corp. is a large generic manufacturer, NDC 00574-7050 competes directly with similar Hydrochlorothiazide 50 mg tablets from all of the above-mentioned manufacturers, as well as numerous smaller regional players.

How Does Regulatory Policy Impact the Price of NDC 00574-7050?

Regulatory policies, both in the United States and globally, exert considerable influence on the pricing of generic pharmaceuticals like Hydrochlorothiazide.

Key Regulatory Influences:

• FDA Approval Process: The Abbreviated New Drug Application (ANDA) process allows for the approval of generic drugs that are bioequivalent to their brand-name counterparts. This streamlined process facilitates market entry for generics, increasing competition and driving down prices.
• Generic Drug User Fee Amendments (GDUFA): GDUFA, reauthorized multiple times, aims to expedite the availability of safe and effective generic drugs by improving the FDA's efficiency in reviewing ANDAs. Faster approvals translate to quicker market entry for generics, intensifying competition.
• Pricing Regulations (Limited Direct Impact): The U.S. has historically had limited direct price controls on pharmaceuticals compared to some other developed nations. However, policies related to Medicare Part D, Medicaid, and PBM regulations indirectly influence pricing by favoring lower-cost generics.
• State-Level Regulations: Some states have implemented measures to monitor or cap drug price increases, though these often target higher-cost specialty drugs rather than mature generics.
• Importation Policies: Debates and potential policy changes regarding drug importation from countries with lower prices could, in theory, affect domestic generic pricing, but the impact on a high-volume generic like Hydrochlorothiazide is less direct than on novel or orphan drugs.
• Manufacturing Standards: Strict FDA oversight of manufacturing facilities and processes ensures product quality but also imposes costs on manufacturers. Non-compliance can lead to recalls and market withdrawal, reducing supply and potentially causing price volatility.

The regulatory environment supports robust generic competition, which is the primary factor suppressing prices for Hydrochlorothiazide. Policies that facilitate generic entry and ensure quality compliance indirectly reinforce the competitive dynamics that keep prices low.

What is the Historical Pricing Trend for Hydrochlorothiazide 50 mg Tablets?

The pricing trend for Hydrochlorothiazide 50 mg tablets, especially in its generic form, has been characterized by a consistent decline over time, punctuated by minor fluctuations.

Historical Pricing Dynamics:

• Initial Post-Patent Erosion: Following patent expiration, generic competition rapidly drove prices down from brand-name levels.
• Continuous Downward Pressure: For over two decades, the generic market for Hydrochlorothiazide has been a volume-driven, highly competitive space. This has led to a steady erosion of prices as manufacturers optimize costs and vie for market share.
• Supply Chain and Rebate Impact: The pricing observed at the pharmacy level is a net price after significant rebates are negotiated with PBMs and payers. The average wholesale price (AWP) or manufacturer's suggested retail price (MSRP) is often a starting point, with actual transaction prices being considerably lower.
• Minor Volatility: Occasional price increases might occur due to:
  • Supply Shortages: Temporary shortages caused by manufacturing issues or increased demand for specific generics can lead to short-term price spikes.
  • Consolidation: Mergers or acquisitions among manufacturers can alter the competitive landscape, potentially leading to adjustments in pricing strategies.
  • Cost Increases: Unforeseen increases in raw material costs or manufacturing expenses, though less impactful on highly commoditized generics.
• Data Sources: Pricing data is typically derived from sources such as:
  • First Databank (FDB): Provides drug pricing information and databases used by healthcare providers.
  • Red Book: Published by First DataBank, it contains drug pricing and reimbursement information.
  • Medicaid Drug Pricing Data: Provides historical pricing for drugs reimbursed by Medicaid.
  • Wholesaler Acquisition Cost (WAC): Represents the price at which a wholesaler purchases a drug from the manufacturer.

Based on available market data and the nature of the generic pharmaceutical market for established drugs, the pricing trend for Hydrochlorothiazide 50 mg tablets (including NDC 00574-7050) has been one of sustained low prices with a general downward trajectory over the long term.

What are the Price Projections for NDC 00574-7050?

Projecting specific prices for a generic drug like Hydrochlorothiazide 50 mg tablets is challenging due to the complex interplay of market forces, particularly rebate structures. However, general trends can be forecasted.

Factors Influencing Future Pricing:

• Continued Generic Competition: The market for Hydrochlorothiazide remains highly saturated with generic options. This intense competition is the primary driver of low prices and will continue to suppress significant price increases.
• Payer and PBM Leverage: PBMs and insurance payers will continue to exert downward pressure on prices through formulary management and aggressive rebate negotiations to control healthcare costs.
• Manufacturing Efficiency: Generic manufacturers will continue to focus on cost optimization in production and supply chain management to maintain competitiveness.
• No Novel Therapies: The absence of disruptive new therapeutic alternatives for hypertension treatment that would directly displace Hydrochlorothiazide ensures its continued demand.
• Potential for Minor Price Adjustments:
  • Slight Increases: Manufacturers might implement minor price increases to account for inflation or modest increases in manufacturing costs. However, these will be constrained by competitive pricing and payer demands.
  • Decreases: Further price declines are possible if new, highly efficient manufacturers enter the market or if existing manufacturers engage in aggressive pricing strategies to gain market share.

Price Projection:

The price for NDC 00574-7050 (Hydrochlorothiazide 50 mg Tablets by Apotex Corp.) is projected to remain stable to slightly declining over the next 3-5 years. Significant price increases are highly unlikely due to the mature generic market, intense competition, and strong payer influence. Actual out-of-pocket costs for patients will continue to be influenced by insurance coverage, co-pays, and pharmacy-specific pricing.

Table 1: Projected Price Trend for NDC 00574-7050 (Hydrochlorothiazide 50 mg Tablets)

Time Horizon	Projected Trend	Primary Drivers
1-2 Years	Stable to Slightly Declining	Intense generic competition, PBM leverage, cost efficiencies.
3-5 Years	Stable to Slightly Declining	Continued market saturation, payer negotiations, manufacturing optimization.

Note: "Price" here refers to the net price realized by the manufacturer after rebates and discounts, or the acquisition cost for pharmacies/wholesalers, not necessarily the list price or patient out-of-pocket cost, which can vary significantly.

Key Takeaways

• NDC 00574-7050 is Hydrochlorothiazide 50 mg Tablets manufactured by Apotex Corp., a widely used generic antihypertensive and diuretic.
• The market is mature and highly competitive, characterized by numerous generic manufacturers and the absence of patent protection for the active pharmaceutical ingredient.
• Intense price competition is the dominant market force, driven by the need to secure formulary placement and capture volume.
• Regulatory policies facilitate generic entry, reinforcing competition and suppressing prices.
• Historical pricing trends for generic Hydrochlorothiazide have shown consistent downward pressure.
• Price projections indicate a stable to slightly declining trend for NDC 00574-7050 over the next 3-5 years, with significant price increases being unlikely.

Frequently Asked Questions

1. What are the primary therapeutic indications for the drug represented by NDC 00574-7050? The drug is indicated for the treatment of hypertension (high blood pressure) and edema (fluid retention) associated with conditions such as congestive heart failure, liver cirrhosis, and renal dysfunction.

2. Does Apotex Corp. hold any exclusive rights or patents related to Hydrochlorothiazide 50 mg Tablets? No, Hydrochlorothiazide is a generic drug whose composition-of-matter patents expired decades ago. Apotex Corp. manufactures and markets a generic version, and therefore does not hold exclusive patent rights for the active ingredient.

3. How do PBMs influence the actual cost of NDC 00574-7050? PBMs negotiate significant rebates with generic manufacturers in exchange for preferred formulary placement. This means the effective price paid by the PBM to the manufacturer, and subsequently influencing the price at the pharmacy, is considerably lower than the list price.

4. What is the typical turnaround time for generic drug approval by the FDA, and how does this affect competition for Hydrochlorothiazide? While turnaround times can vary, the FDA's ANDA process, particularly with initiatives like GDUFA, aims to expedite generic approvals. Faster approvals for Hydrochlorothiazide mean more competitors can enter the market quickly, intensifying competition and driving prices down.

5. Are there any significant upcoming regulatory changes expected to impact the pricing of Hydrochlorothiazide 50 mg tablets? While no specific major regulatory changes are immediately anticipated to drastically alter the pricing of this mature generic, ongoing policy discussions around drug pricing, Medicare negotiation powers, and importation could indirectly influence the overall market dynamics for all pharmaceuticals, including generics. However, direct price controls on such a commoditized generic are unlikely.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). National Drug Code (NDC) Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/search-national-drug-code-directory

[2] Generic Pharmaceutical Association. (n.d.). History of Generics. Retrieved from https://www.appc.org/history-of-generics/ (Note: While a specific document on Hydrochlorothiazide patent expiration is not publicly available as a standalone link, the general historical context of its patent expiry is widely accepted in pharmaceutical literature and industry knowledge, with patents typically expiring within 17 years of grant for drugs approved in the mid-20th century.)